Back
Influence of interferon beta-1a dose frequency on PBMC cytokine secretion and biological effect markers.
Journal article

Influence of interferon beta-1a dose frequency on PBMC cytokine secretion and biological effect markers.

Show more…
  • 1999-09-25
Published in:
  • Journal of neuroimmunology. - 1999
2',5'-Oligoadenylate Synthetase
Adult
Dose-Response Relationship, Immunologic
Drug Administration Schedule
Fatigue
Fever
Headache
Humans
Immunologic Factors
Interferon beta-1a
Interferon-beta
Interferon-gamma
Interleukin-1
Interleukin-6
Lymphocyte Activation
Lymphokines
Lymphotoxin-alpha
Male
Neopterin
Recombinant Proteins
Safety
T-Lymphocytes
Tumor Necrosis Factor-alpha
beta 2-Microglobulin
English Interferon-beta regimens for immune-mediated diseases, such as multiple sclerosis (MS), have not been compared regarding their biological effects. In this randomized, parallel-group, placebo-controlled study, cytokine secretion by mitogen-stimulated PBMCs and serum response markers were assessed in volunteers receiving subcutaneous recombinant IFN beta-1a (Rebif, Ares-Serono) 22 microg once a week (QW), 22 microg three times a week, 66 microg QW, or placebo. The production of IL-1beta, IL-6, IFN-gamma, TNF-alpha and TNF-beta markedly decreased during 24-48 h after each injection, with limited dose-dependency and no evidence of tolerance or effect augmentation over 1 month. IL-10 secretion remained unchanged. The increase in serum beta2-microglobulin, neopterin and 2-5A-synthetase was more sustained. Thus, IFN-beta-induced immunomodulation in vivo strongly depends on the administration schedule, the time-integrated effect being 2-3 times greater when a same weekly dose is divided in three injections.
Language
  • English
Open access status
closed
Identifiers
Persistent URL
https://sonar.ch/global/documents/289261
Statistics
Document views: 20 File downloads: